Comparative Pharmacology
Head-to-head clinical analysis: INDERAL LA versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERAL LA versus TRANDATE.
INDERAL LA vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also inhibits renin release and reduces sympathetic outflow.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
Initial: 80 mg orally once daily; titrate to 120-160 mg once daily; maximum 640 mg/day.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Terminal elimination half-life is 8-11 hours (range 4-16 hours) after oral administration. The extended-release formulation (INDERAL LA) results in a prolonged half-life of approximately 10 hours, allowing once-daily dosing.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Primarily hepatic metabolism with renal elimination of metabolites. Less than 1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 20% of eliminated dose.
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker